Current immunomodulatory therapies for multiple sclerosis

Formulary

Volumn 39, Issue 11 SUPPL., 2004, Pages 4-10

  Smith, Craig H ^a,b  

^a GENENTECH INC   (United States)

^b NONE   (United States)

Author keywords

Glatiramer acetate; Interferon beta; Multiple sclerosis

Indexed keywords

AMANTADINE; AMITRIPTYLINE; BACLOFEN; BETA INTERFERON; BETA1A INTERFERON; BIOLOGICAL FACTOR; BISACODYL; CARBAMAZEPINE; CLONAZEPAM; DANTROLENE; DOCUSATE SODIUM; FLAVOXATE; FLUOXETINE; GABAPENTIN; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; MITOXANTRONE; MODAFINIL; NATALIZUMAB; OXYBUTYNIN; PEMOLINE; PHENYTOIN; PROPANTHELINE BROMIDE; PSYLLIUM HYDROCOLLOID; SENOKOT; SEROTONIN UPTAKE INHIBITOR; TIZANIDINE; TOLTERODINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ADJUVANT THERAPY; AUTOIMMUNE DISEASE; BALANCE DISORDER; BLADDER DYSFUNCTION; BLOOD TOXICITY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC DISEASE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL DISEASE; HEREDITY; HUMAN; HYPERSENSITIVITY REACTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; INFLAMMATION; INJECTION PAIN; INJECTION SITE; LEUKOPENIA; LIVER DISEASE; MENSTRUATION DISORDER; MONOTHERAPY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NAUSEA; NEUROLOGIC DISEASE; NEUROPROTECTION; OPEN STUDY; PAIN; PARESTHESIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SPASTICITY; URTICARIA; VISUAL DISORDER;

EID: 9244227932     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221-1231.
2. National Institute of Neurological Disorders and Stroke. Multiple Sclerosis: Hope Through Research. Available at: http://www.ninds.nih.gov/ health_and_medical/pubs/multiple_sclerosis.htm. Accessed September 24, 2004.
3. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med. 2000;343:938-952.
4. Roessler RT, Rumrill PD Jr. Multiple sclerosis and employment barriers: a systemic perspective on diagnosis and intervention. Work. 2003;21:17-23.
5. Hakim EA, Bakheit AM, Bryant TN, et al. The social impact of multiple sclerosis-a study of 305 patients and their relatives. Disabil Rehabil. 2000;22:288-293.
6. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996;46:907-911.
7. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989;112:133-146.
8. Baranzini SE, Oksenberg JR, Hauser SL. New insights into the genetics of multiple sclerosis. J Rehabil Res Dev. 2002;39:201-209.
9. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. N Engl J Med. 1998;338:278-285.
10. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neurodegeneration in multiple sclerosis. Ann Neurol. 2002;52:650-653.
11. Halper J. Best practices in the nursing care of multiple sclerosis: disease management, pharmacologic treatment, and nursing research. Paper presented at: 11th Annual Meeting of the European Neurological Society; April 21-25, 2001; Paris, France.
12. Avonex® full Prescribing Information. Cambridge, Mass: Biogen Idec Inc; 2004.
13. Rebif® full Prescribing Information. Rockland, Mass: Serono; 2002.
14. Betaseron® full Prescribing Information. Montville, NJ: Berlex Laboratories; 2003.
15. Copaxone® full Prescribing Information. Kansas City, Mo: Teva Pharmaceutical Industries Ltd; 2002.
16. Novantrone® full Prescribing Information. Seattle, Wash: Immunex Corporation; 2002.
17. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty D; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Uses of mitoxantrone (Novatrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003;61:1332-1338.
18. National Multiple Sclerosis Society. Expert Opinion Paper. Disease Management Consensus Statement. Available at: http//www.nationalmssociety.org/ Expert Opinion Papers.asp. Accessed August 31, 2004.
19. Goodin DS, Frohman EM, Garmany GP Jr, et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58:169-178.
20. Freedman MS, Blumhardt LD, Brochet B, et al; Paris Working Group. International consensus statement on the use of disease-modifying agents in multiple sclerosis. Mult Scler. 2002;8:19-23.
21. Yong VW, Chabot S, Stuve O, Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998;51:682-689.
22. Kieseier BC, Seifert T, Giovannoni G, Hartung HP. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology. 1999;53:20-25.
23. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45:1277-1285.
24. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II: MRI analysis results of a multicenter randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993;43:662-667.
25. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39:285-294.
26. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352:1498-1504.
27. PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology. 2001;56:1628-1636.
28. Panitch H, Goodin DS, Francis G, et al; Evidence Study Group. Evidence of Interferon Dose-response: European North American Comparative Efficacy; University of British Columbia MS/MRI Research Group. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology. 2002;59:1496-1506.
29. Teitelbaum B, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol. 1971;1:242-248.
30. Kayhan B, Aharoni R, Arnon R. Glatiramer acetate (Copaxone) regulates nitric oxide and related cytokine secretion in experimental autoimmune encephalomyelitis. Immunol Lett. 2003;88:185-192.
31. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998;50:701-708.
32. Johnson KP, Brooks BR, Ford CC, et al. Results of the long-term (eight-year) prospective, open label trial of glatiramer acetate for relapsing multiple sclerosis. Neurology. 2002;58(Suppl 3):A458.
33. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler. 2000;6:255-266.
34. Johnson KP, Panitch HS, Ford CC, Lisak RP, and the Copaxone Study Group. Long-term slowing of disability progression in patients receiving continuous glatiramer acetate compared with those withdrawing from therapy: 10 year results from an ongoing trial. Paper presented at: 56th Annual Meeting of the American Academy of Neurology; April 24-May 1, 2004; San Francisco, Calif. Abstract S20.004.
35. Comi G, Filippi M, Wolinsky JS. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol. 2001;49:290-297.
36. Wolinsky JS, Comi G, Filippi M, Ladkani D, Kadosh S, Shifroni G; European/Canadian Glatiramer Acetate Study Group. Copaxone's effect on MRI-monitored disease in relapsing MS is reproducible and sustained. Neurology. 2002;59:1284-1286.
37. Yong VW. Differential mechanisms of action of interferon-beta and glatiramer acetate in MS. Neurology. 2002;59:802-808.
38. Rosenberg GA, Dencoff JE, Correa N Jr, Reiners M, Ford CC. Effects of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology. 1996;46:1626-1632.
39. Waubant E, Goodkin DE, Gee L, et al. Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis. Neurology. 1999;53:1397-1401.
40. Aharoni R, Teitelbaum D, Leitner O, Meshorer A, Sela M, Arnon R. Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1. Proc Natl Acad Sci U S A. 2000;97:11472-11477.
41. Sormani MP, Bruzzi P, Comi G, Filippi M. MRI metrics as surrogate markers for clinical relapse rate in relapsing-remitting MS patients. Neurology. 2002;58:417-421.
42. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G; European/Canadian Glatiramer Acetate Study Group. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology. 2001;57:731-733.
43. Vartanian T, Solberg Sorensen P, Rice G. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis. J Neurol. 2004;251(Suppl 2):II25-II30.
44. Bertolotto A, Sala A, Malucchi S, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry. 2004;75:1294-1299.
45. Ross C, Clemmesen KM, Svenson M, et al. Immunogenicity of interferon-beta in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration. Danish Multiple Sclerosis Study Group. Ann Neurol. 2000;48:706-712.
46. Sorensen PS, Ross C, Clemmesen KM, et al; Danish Multiple Sclerosis Study Group. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet. 2003;362:1184-1191.
47. Reske D, Walser A, Haupt WF, Petereit HF. Long-term persisting interferon beta-1b neutralizing antibodies after discontinuation of treatment. Acta Neurol Scand. 2004;109:66-70.
48. Brenner T, Arnon R, Sela A, et al. Humoral and cellular response to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol. 2001;115:152-160.
49. Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf. 2001;24:979-990.
50. Khan OA, Tselis AC, Kamholz JA, Garbern JY, Lewis RA, Lisak RP. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFN beta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol. 2001;8:141-148.
51. Carra A, Onaha P, Sinay V, et al. A retrospective, observational study comparing the four available immunomodulatory treatments for relapsing-remitting multiple sclerosis. Eur J Neurol. 2003;10:671-676.
52. Fletcher S, Vardi J, Pollak L, Rabey JM. A prospective, open label treatment trial to compare the effect of IFN-β1a (Avonex) and IFN-β1b (Betaseron) and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis. Eur J Neurol. 2001;8:141-148.
53. Haas J. Onset of clinical benefit of glatiramer (Copaxone) acetate in 255 patients with relapsing-remitting multiple sclerosis. Paper presented at: 55th Annual Meeting of the American Academy of Neurology; 2003; Honolulu, Hawaii. Abstract P06.105.
54. Galetta SL, Markowitz C, Lee AG. Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch Intern Med. 2002;162:2161-2169.
55. Lublin F, Baier M, Cutter G, et al. Results of the extension of the trial to assess the longer term safety of combining interferon beta 1a and glatiramer acetate. Neurology. 2002;58(S3):A85.